Free Access
Tableau I.
Inhibiteurs des galectines en cours d’évaluation clinique.
| Composés | Cibles | Indications | Phase clinique | Entreprise | Réf |
|---|---|---|---|---|---|
| Polysaccharides | |||||
| Pectine citrique modifiéeGCS-100(polymères réticulés principalement composés d’acide galacturonique, de galactose et de rhamnose) | Gal-3* | Fibrose rénale chroniqueCancer (leucémies, myélomes, chimio-immunothérapie des lymphomes) | Phase 2aPhase 2Phase 1 | La Jolla Pharma-ceutical(GlycoGenesys/ Prospect Therapeutics) | [34–36] |
| GM-CT-01(Davanat®) | Gal-3, Gal-1 (sélectivité ×3 en faveur de Gal-3) | Cancer colorectalCholangiocarcinome | Phase 2Phase 2 | Galectin Therapeutics (Pro-Pharmaceuticals Inc) | [37] |
| GR-MD-02Galactoarabino-rhamnogalacturonan | Gal-3, Gal-1 | MélanomeStéatose hépatique | Phase 1Phase 1 | Galectin Therapeutics (Pro-Pharmaceuticals Inc) | |
| Peptidomimétiques | |||||
| PTX-008 | Gal-1 | Cancer (angiogenèse) | Phase 1 | OncoEthix, Inc | [38] |
| Petites molécules dérivées de sucres | |||||
| TD139 | Gal-3/Gal-1 | Fibrose pulmonaire | Phase 1/2a | Galecto Biotech | [39] |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.